Bank of Montreal’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bank of Montreal’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$252K	Buy	38,457 +207	+0.5%	+$1.43K	﹤0.01%	2868
2026 Q1	$276K	Buy	38,250 +1,000	+3%	+$8.05K	﹤0.01%	2726
2025 Q4	$280K	Hold	37,250	–	–	﹤0.01%	2636
2025 Q3	$219K	Hold	37,250	–	–	﹤0.01%	2721
2025 Q2	$215K	Sell	37,250 -15,000	-29%	-$57.6K	﹤0.01%	2774
2025 Q1	$171K	Sell	52,250 -4,500	-8%	-$15.5K	﹤0.01%	2776
2024 Q4	$178K	Buy	56,750 +7,500	+15%	+$22.2K	﹤0.01%	2801
2024 Q3	$126K	Hold	49,250	–	–	﹤0.01%	3184
2024 Q2	$133K	Buy	+49,250	New	+$137K	﹤0.01%	3161

Other funds holding EPRX

BGC

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Bank of Montreal's EPRX Position: Q2 2026 in Review

Bank of Montreal increased its Eupraxia Pharmaceuticals (EPRX) stake by 0.54% in Q2 2026, buying an estimated $1.43K and bringing the position to 38,457 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #2868.

Bank of Montreal first reported a position in EPRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $280K in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

Bank of Montreal held 38,457 shares of Eupraxia Pharmaceuticals worth $252K as of Q2 2026.
Bank of Montreal bought 207 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $1.43K.
Eupraxia Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #2868 holding.
Bank of Montreal first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Bank of Montreal's Eupraxia Pharmaceuticals position peaked at $280K in Q4 2025.
67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.